Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Japan’s Eisai and US biotech major Biogen have announced that the latest findings demonstrating the benefits of continuous ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...

BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for their fiscal year (FY) 2024 ...

Eisai: Leqembi Approved In EU (Rating Downgrade) Jun. 10, 2025 2:46 AM ET Eisai Co., Ltd. (ESALF) Stock, ESAIY Stock ESALF, ESAIY Valkyrie Trading Society Investing Group Leader ...

Eisai aims to submit a LEQEMBI SC formulation Biologics License Application (BLA) with the U.S. Food and Drug Administration by March 31, 2024. 2.